Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03078322 · ClinicalTrials.gov registry record · Phase 2
AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression
A Phase 2 study, sponsored by VistaGen Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT03078322: Completed Phase 2 study, sponsored by VistaGen Therapeutics.
NCT03078322 is a Phase 2 study that has completed, run by VistaGen Therapeutics. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03078322, a Phase 2 study, has completed, sponsored by VistaGen Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The study will evaluate the safety and efficacy of AV-101.
Primary Outcome
Depression questionnaire
Interventions
- DRUG Placebo
- DRUG AV-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2018-03-05 |
| Est. Completion | 2019-10-01 |
| Phase | Phase 2 |
What the finished NCT03078322 record still lists
NCT03078322 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03078322 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03078322 about?
NCT03078322 is a clinical study titled "AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression". The study will evaluate the safety and efficacy of AV-101.
What is the current status of trial NCT03078322?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2018-03-05. Estimated completion is 2019-10-01.
What interventions are being tested in trial NCT03078322?
The interventions under investigation include: Placebo (DRUG), AV-101 (DRUG).
Who is sponsoring clinical trial NCT03078322?
This trial is sponsored by VistaGen Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03078322's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI